Journal article
Associations of Chronic Kidney Disease Markers with Cognitive Function: A 12-Year Follow-Up Study
JW Sacre, DJ Magliano, PZ Zimmet, KR Polkinghorne, SJ Chadban, KJ Anstey, JE Shaw
Journal of Alzheimer S Disease | IOS PRESS | Published : 2019
DOI: 10.3233/JAD-180498
Abstract
Background: The role of chronic kidney disease (CKD) as a risk factor for cognitive impairment independent of their shared antecedents remains controversial. Objective: To determine whether kidney damage (indicated by albuminuria) or kidney dysfunction (estimated glomerular filtration rate [eGFR] <60 ml/min/1.73 m2) predict future (12-year) cognitive function independently of their shared risk factors. Methods: We studied 4,128 individuals from the 1999/00 population-based Australian Diabetes, Obesity, and Lifestyle (AusDiab) Study who returned in 2011/12 for follow-up cognitive function testing. Albuminuria was defined by urinary albumin:creatinine≥3.5 (women) or≥2.5 mg/mmol (men). Kidney d..
View full abstractRelated Projects (2)
Grants
Awarded by Bristol-Myers Squibb
Funding Acknowledgements
The AusDiab study, co-coordinated by the Baker Heart and Diabetes Institute, gratefully acknowledges the support and assistance given by: R Atkins, B Balkau, E Barr, A Cameron, M de Courten, D Dunstan, A Kavanagh, S Murray, N Owen, T Welborn, and all the study participants. Funding or logistical support was provided by the National Health and Medical Research Council (NHMRC grants #233200, #1007544, and #1100579; KJA was also supported by a NHMRC Fellowship [#1102694]), the Australian Government Department of Health and Ageing, Abbott Australasia Pty Ltd, Alphapharm Pty Ltd, Amgen Australia, AstraZeneca, Bristol-Myers Squibb, City Health Centre-Diabetes Service-Canberra, Department of Health and Community Services-Northern Territory, Department of Health and Human Services-Tasmania, Department of Health-New South Wales, Department of Health-Western Australia, Department of Health-South Australia, Department of Human Services-Victoria, Diabetes Australia, Diabetes Australia Northern Territory, Eli Lilly Australia, Estate of the Late Edward Wilson, GlaxoSmithKline, Jack Brockhoff Foundation, Janssen-Cilag, Kidney Health Australia, Marian & FH Flack Trust, Menzies Research Institute, Merck Sharp & Dohme, Novartis Pharmaceuticals, Novo Nordisk Pharmaceuticals, Pfizer Pty Ltd, Pratt Foundation, Queensland Health, Roche Diagnostics Australia, Royal Prince Alfred Hospital-Sydney, Sanofi Aventis, sanofi-synthelabo, and the Victorian Government's OIS Program. No funding providers played a role in study design/conduct, analysis/interpretation of data, or manuscript preparation.